Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly - What can't weight-loss meds do? Eli Lilly is going to test Zepbound as a treatment for addiction - Eli Lilly is partnering with Ro to make it easier than ever to get Zepbound - Eli Lilly's obesity drug beats rival in head-to-head trial -- where Cramer sees shares going next - Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial - Eli Lilly to launch diabetes, obesity drug in India next year - Stocks making the biggest moves midday: JetBlue, Eli Lilly, Pure Storage, Salesforce and more - Here are Thursday's biggest analyst calls: Nvidia, Tesla, Eli Lilly, Cheesecake Factory, Walmart, Costco, Broadcom & more - Eli Lilly Chief Says He Will Fight for the FDA, Challenging RFK Jr.'s Stance - Eli Lilly says Zepbound beat rival weight loss drug Wegovy in head-to-head study